Biblio
Up-regulation of ABCG2 by MYBL2 deletion drives Chlorin e6-mediated photodynamic therapy resistance in colorectal cancer. Photodiagnosis Photodyn Ther. 2023:103558.
Targeted photodynamic therapy of glioblastoma mediated by platelets with photo-controlled release property. Biomaterials. 2022;290:121833.
. A nanoreactor boosts chemodynamic therapy and ferroptosis for synergistic cancer therapy using molecular amplifier dihydroartemisinin. J Nanobiotechnology. 2022;20(1):230.
Metal-organic framework-encapsulated dihydroartemisinin nanoparticles induces apoptotic cell death in ovarian cancer by blocking ROMO1-mediated ROS production. J Nanobiotechnology. 2023;21(1):204.
. Macrophages mediated delivery of chlorin e6 and treatment of lung cancer by photodynamic reprogramming. Int Immunopharmacol. 2021;100:108164.
Laser-triggered intelligent drug delivery and anti-cancer photodynamic therapy using platelets as the vehicle. Platelets. 2023;34(1):2166677.
Harnessing chlorin e6 loaded by functionalized iron oxide nanoparticles linked with glucose for target photodynamic therapy and improving of the immunogenicity of lung cancer. J Cancer Res Clin Oncol. 2022.
Ferroptosis triggered by dihydroartemisinin facilitates chlorin e6 induced photodynamic therapy by inhibiting GPX4 and enhancing ROS. Eur J Pharmacol. 2022:174797.
Dihydroartemisinin-driven TOM70 inhibition leads to mitochondrial destabilization to induce pyroptosis against lung cancer. Phytother Res. 2024.
Dihydroartemisinin-driven selective anti-lung cancer proliferation by binding to EGFR and inhibition of NRAS signaling pathway-induced DNA damage. Sci Rep. 2024;14(1):11704.
Chlorin e6 mediated photodynamic therapy triggers resistance through ATM-related DNA damage response in lung cancer cells. Photodiagnosis Photodyn Ther. 2021:102645.
Cepharanthine synergizes with photodynamic therapy for boosting ROS-driven DNA damage and suppressing MTH1 as a potential anti-cancer strategy. Photodiagnosis Photodyn Ther. 2023:103917.